However, at variance with our data, a recent study [11] showed that a post-treatment algorithm combining age/albumin/TE and, optionally, alfafetoprotein and alcohol intake enables a reliable risk stratification for the development of HCC, even among cirrhotic patients, identifying a large proportion of patients with an HCC risk < 1%/year, below the threshold considered to be cost-effective. The gene discussed is ALB; the disease is hepatocellular carcinoma.